AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections

Genital Human Papilloma Virus Infection Clinical Trial

Official title: Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load

Status Active, not recruiting

Clinical Trial Summary

This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV) infection.

• Primary endpoint: significant drop in viral load AV2-DM versus placebo

• Secondary endpoint:the number of patients with adverse events

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Genital Human Papilloma Virus Infection
• Papillomavirus Infections
• Virus Diseases

• NCT number: NCT01654822
• Study type: Interventional
• Source: Cesa Projects International
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 2012
• Completion date: January 2013